---
title: "Anemia"
order: 1
category: "Hematology"
---

# Anemia

## Overview

Anemia is defined as a reduction in the number of red blood cells (RBCs), hemoglobin (Hgb) concentration, or hematocrit (Hct) below the reference range for age and sex. Anemia is not a diagnosis itself but rather a manifestation of underlying disease. It affects approximately 1.62 billion people globally, making it one of the most common hematologic abnormalities encountered in clinical practice.

### Definition

**WHO criteria**:
- Men: Hemoglobin <13 g/dL
- Non-pregnant women: Hemoglobin <12 g/dL
- Pregnant women: Hemoglobin <11 g/dL
- Children (6 months-6 years): Hemoglobin <11 g/dL
- Children (6-14 years): Hemoglobin <12 g/dL

**Severity classification**:
- Mild: Hemoglobin 10-12 g/dL (women), 10-13 g/dL (men)
- Moderate: Hemoglobin 8-10 g/dL
- Severe: Hemoglobin <8 g/dL
- Life-threatening: Hemoglobin <6.5 g/dL

### Classification

**By MCV (mean corpuscular volume)**:
- **Microcytic** (MCV <80 fL): Iron deficiency, thalassemia, anemia of chronic disease, sideroblastic anemia
- **Normocytic** (MCV 80-100 fL): Acute blood loss, hemolysis, anemia of chronic disease, chronic kidney disease, aplastic anemia
- **Macrocytic** (MCV >100 fL): Megaloblastic (B12/folate deficiency), non-megaloblastic (alcohol, liver disease, hypothyroidism, myelodysplasia)

**By mechanism**:
- **Decreased production**: Nutritional deficiency, bone marrow failure, chronic disease, chronic kidney disease
- **Increased destruction**: Hemolytic anemias (immune, hereditary, microangiopathic)
- **Blood loss**: Acute or chronic bleeding

**By reticulocyte count**:
- **Low reticulocyte count** (<2%): Production defect (bone marrow failure, nutritional deficiency)
- **High reticulocyte count** (>2%): Destruction (hemolysis) or loss (bleeding)

### Epidemiology

- Global prevalence: 24.8% of population
- Most affected: Preschool children (47.4%), pregnant women (41.8%)
- Iron deficiency: Most common cause worldwide (50% of all anemia)
- Developing countries: Higher prevalence due to malnutrition, parasitic infections
- Economic burden: Reduced work productivity, impaired cognitive development

## Pathophysiology

### Iron Deficiency Anemia

**Iron metabolism**:
- Total body iron: 3-4 g in adults
- Distribution:
  - Hemoglobin: 65-70%
  - Storage (ferritin, hemosiderin): 25-30%
  - Myoglobin: 3-5%
  - Enzymes: 1-2%
- Daily requirement: Men 1 mg, menstruating women 2 mg
- Absorption: Duodenum and proximal jejunum (10% of dietary iron)

**Mechanisms of iron deficiency**:
- **Decreased intake**: Poor diet, vegetarian diet
- **Decreased absorption**: Gastrectomy, celiac disease, H. pylori infection, proton pump inhibitors
- **Increased loss**: Chronic blood loss (GI bleeding, menorrhagia)
- **Increased demand**: Pregnancy, lactation, rapid growth

**Stages of iron deficiency**:
1. **Iron depletion**: Decreased ferritin, normal hemoglobin
2. **Iron deficient erythropoiesis**: Decreased transferrin saturation, increased TIBC, normal hemoglobin
3. **Iron deficiency anemia**: Microcytic, hypochromic anemia

**Hematologic effects**:
- Reduced hemoglobin synthesis
- Microcytic, hypochromic RBCs
- Increased RDW (red cell distribution width)
- Thrombocytosis (reactive)

### Megaloblastic Anemia

**Vitamin B12 (cobalamin) deficiency**:

*Metabolism*:
- Absorption: Intrinsic factor (IF) from gastric parietal cells binds B12, absorbed in terminal ileum
- Storage: Liver stores 2-5 mg (3-5 years supply)
- Functions: DNA synthesis (methionine synthase, methylmalonyl-CoA mutase)

*Causes*:
- **Decreased intake**: Vegan diet, malnutrition
- **Malabsorption**:
  - Pernicious anemia (autoimmune destruction of parietal cells)
  - Gastrectomy, gastric bypass
  - Pancreatic insufficiency
  - Terminal ileum disease (Crohn's disease) or resection
  - Diphyllobothrium latum (fish tapeworm)
- **Medications**: Metformin, proton pump inhibitors, H2-blockers
- **Congenital**: Transcobalamin II deficiency

*Pathophysiology*:
- Impaired DNA synthesis
- Megaloblastic changes: Nuclear-cytoplasmic asynchrony
- Ineffective erythropoiesis
- Hypersegmented neutrophils
- Neurologic effects: Demyelination of posterior columns and lateral corticospinal tracts

**Folate deficiency**:

*Metabolism*:
- Absorption: Proximal jejunum
- Storage: Liver stores 5-20 mg (3-4 months supply)
- Functions: DNA synthesis (thymidine synthesis, purine synthesis)

*Causes*:
- **Decreased intake**: Poor diet, alcoholism, elderly
- **Malabsorption**: Celiac disease, tropical sprue
- **Increased demand**: Pregnancy, lactation, hemolytic anemia, malignancy
- **Medications**: Methotrexate, trimethoprim, phenytoin, sulfasalazine
- **Dialysis**: Folate loss

*Pathophysiology*:
- Similar to B12 deficiency (megaloblastic changes)
- No neurologic manifestations

### Hemolytic Anemias

**General features**:
- Shortened RBC lifespan (<120 days)
- Compensatory increase in erythropoiesis (reticulocytosis)
- Elevated indirect bilirubin, LDH
- Decreased haptoglobin
- Hemoglobinuria in severe intravascular hemolysis

**Hereditary spherocytosis**:
- Autosomal dominant (75%), sporadic (25%)
- Defects in RBC membrane proteins (spectrin, ankyrin, band 3)
- Loss of membrane surface area → spherical cells
- Splenic sequestration and hemolysis

**G6PD deficiency**:
- X-linked recessive
- Most common enzymatic disorder (400 million affected)
- G6PD protects RBCs from oxidative stress
- Hemolysis triggered by oxidative stress:
  - Infections, medications (antimalarials, sulfonamides, dapsone), fava beans
- Bite cells, Heinz bodies on smear

**Sickle cell disease**:
- Autosomal recessive
- Mutation in β-globin gene (HbS)
- Deoxygenation → HbS polymerization → RBC sickling
- Vaso-occlusive crises, hemolytic anemia
- Complications: Stroke, acute chest syndrome, priapism, avascular necrosis

**Autoimmune hemolytic anemia (AIHA)**:

*Warm AIHA*:
- IgG antibodies active at 37°C
- Extravascular hemolysis (spleen)
- Causes: Idiopathic, CLL, lymphoma, SLE, drugs (penicillin, methyldopa, cephalosporins)
- Positive direct antiglobulin test (DAT/Coombs)

*Cold agglutinin disease*:
- IgM antibodies active at <37°C
- Intravascular hemolysis
- Causes: Idiopathic, Mycoplasma pneumoniae, infectious mononucleosis, lymphoma
- Acrocyanosis in cold exposure

**Microangiopathic hemolytic anemia (MAHA)**:
- Mechanical destruction of RBCs by intravascular abnormalities
- Schistocytes (fragmented RBCs) on smear
- Causes:
  - Thrombotic thrombocytopenic purpura (TTP)
  - Hemolytic uremic syndrome (HUS)
  - Disseminated intravascular coagulation (DIC)
  - HELLP syndrome (hemolysis, elevated liver enzymes, low platelets in pregnancy)
  - Mechanical heart valves

### Anemia of Chronic Disease

**Mechanisms**:
- Inflammatory cytokines (IL-6, TNF-α) stimulate hepcidin production
- Hepcidin inhibits ferroportin → traps iron in macrophages and enterocytes
- Reduced iron availability for erythropoiesis
- Decreased erythropoietin production/response
- Shortened RBC lifespan
- Blunted erythroid progenitor response

**Characteristics**:
- Normocytic or microcytic
- Low serum iron, low TIBC, normal/elevated ferritin
- Distinguishes from iron deficiency (low ferritin in IDA)

**Associated conditions**:
- Chronic infections (tuberculosis, HIV, osteomyelitis)
- Inflammatory diseases (rheumatoid arthritis, SLE, IBD)
- Malignancy
- Chronic kidney disease

### Sideroblastic Anemia

**Definition**:
- Ringed sideroblasts: Erythroblasts with iron-laden mitochondria forming ring around nucleus
- Impaired heme synthesis despite adequate iron

**Types**:
- **Hereditary**: X-linked (ALAS2 mutation), autosomal
- **Acquired**: Myelodysplastic syndrome, alcohol, lead poisoning, copper deficiency
- **Medications**: Isoniazid, chloramphenicol, linezolid

**Characteristics**:
- Microcytic or dimorphic anemia
- Elevated ferritin, transferrin saturation
- Bone marrow: Ringed sideroblasts on Prussian blue stain

### Aplastic Anemia

**Definition**:
- Pancytopenia with hypocellular bone marrow (<25% cellularity)
- Failure of hematopoietic stem cells

**Causes**:
- **Idiopathic**: 50-70% of cases
- **Acquired**:
  - Medications: Chloramphenicol, carbamazepine, gold, sulfonamides
  - Chemicals: Benzene, insecticides
  - Viral infections: Hepatitis, EBV, CMV, HIV, parvovirus B19
  - Pregnancy
  - Autoimmune diseases
- **Inherited**: Fanconi anemia, dyskeratosis congenita

**Pathophysiology**:
- Immune-mediated destruction of hematopoietic stem cells (T-cell mediated)
- Direct stem cell damage
- Microenvironmental defects

**Severity**:
- **Severe**: ANC <500/μL, platelet count <20,000/μL, or reticulocyte count <20,000/μL
- **Very severe**: ANC <200/μL

## Clinical Presentation

### Symptoms

**General anemia symptoms** (related to tissue hypoxia):
- Fatigue, weakness, malaise
- Dyspnea on exertion
- Dizziness, lightheadedness
- Headache
- Decreased exercise tolerance
- Palpitations
- Chest pain (angina) in patients with coronary artery disease
- Syncope (severe anemia)

**Symptom severity**:
- Correlates with rapidity of onset more than absolute hemoglobin level
- Acute blood loss: Symptoms at higher hemoglobin levels
- Chronic anemia: May be asymptomatic even with severe anemia (compensatory mechanisms)

### Iron Deficiency-Specific

- **Pica**: Craving for non-food items (ice, dirt, clay)
- **Pagophagia**: Craving for ice (specific for iron deficiency)
- **Koilonychia**: Spoon-shaped nails
- **Angular cheilitis**: Cracks at corners of mouth
- **Glossitis**: Smooth, sore tongue
- **Restless legs syndrome**
- **Hair loss**
- **Brittle nails**

### Megaloblastic Anemia-Specific

**B12 deficiency**:
- **Neurologic manifestations**:
  - Paresthesias (hands, feet)
  - Loss of vibration and position sense
  - Ataxia, gait disturbance
  - Cognitive impairment, memory loss, dementia
  - Depression, psychosis
  - Subacute combined degeneration of spinal cord
- **Glossitis**: Beefy red, smooth tongue
- **Hyperpigmentation**
- **Neurologic symptoms may occur without anemia**

**Folate deficiency**:
- No neurologic manifestations
- Glossitis
- May mask B12 deficiency anemia (but not neurologic symptoms)

### Hemolytic Anemia-Specific

- **Jaundice**: Elevated indirect bilirubin
- **Dark urine**: Hemoglobinuria (intravascular hemolysis)
- **Splenomegaly**: Extravascular hemolysis
- **Sickle cell crisis**: Severe pain, fever, acute chest syndrome
- **Cold-induced symptoms**: Cold agglutinin disease (acrocyanosis, Raynaud's)

### Aplastic Anemia-Specific

- **Anemia symptoms**: Fatigue, weakness
- **Neutropenia**: Recurrent infections, fever
- **Thrombocytopenia**: Petechiae, purpura, bleeding (gums, nose)

### Physical Examination

**General findings**:
- **Pallor**: Conjunctivae, palmar creases, nail beds
- **Tachycardia**: Compensatory
- **Flow murmurs**: Increased cardiac output
- **Hypotension**: Severe anemia, acute blood loss
- **Orthostatic vital signs**: Volume depletion

**Iron deficiency**:
- Koilonychia, angular cheilitis, glossitis
- Atrophic gastritis (pernicious anemia overlap)

**Megaloblastic anemia**:
- Glossitis (smooth, beefy red tongue)
- Hyperpigmentation (B12 deficiency)
- Decreased vibration/position sense, ataxia (B12 deficiency)
- Positive Romberg sign

**Hemolytic anemia**:
- Jaundice (scleral icterus)
- Splenomegaly
- Hepatomegaly (chronic hemolysis)

**Aplastic anemia**:
- Petechiae, purpura, ecchymoses
- No organomegaly (distinguishes from leukemia)

## Diagnosis

### Initial Evaluation

**Complete blood count (CBC) with differential**:
- Hemoglobin, hematocrit
- MCV, MCH, MCHC
- RDW (red cell distribution width)
- Reticulocyte count
- White blood cell count and differential
- Platelet count

**Peripheral blood smear**:
- RBC morphology
- WBC morphology
- Platelet morphology

**Reticulocyte count**:
- Normal: 0.5-2%
- Reticulocyte index = (Patient Hct/Normal Hct) × Reticulocyte %
- Corrected reticulocyte count <2%: Production defect
- Corrected reticulocyte count >2%: Hemolysis or blood loss

### Iron Deficiency Anemia

**Laboratory findings**:
- **CBC**: Microcytic, hypochromic anemia (low MCV, low MCH)
- **Elevated RDW**: Anisocytosis
- **Low serum iron**: <50 μg/dL
- **Elevated TIBC**: >450 μg/dL
- **Low transferrin saturation**: <15%
- **Low ferritin**: <15 ng/mL (most specific)
  - Ferritin is acute phase reactant (may be normal/elevated in inflammation)
- **Thrombocytosis**: Reactive (mild)

**Peripheral smear**:
- Microcytic, hypochromic RBCs
- Anisopoikilocytosis
- Target cells
- Pencil cells

**Workup for source of blood loss**:
- **Men and postmenopausal women**: GI workup (colonoscopy, upper endoscopy)
- **Premenopausal women**: Menstrual history, consider GI workup if not explained by menorrhagia
- **Stool guaiac**: Assess for occult GI bleeding
- **Celiac serology**: Tissue transglutaminase antibodies (especially if refractory to treatment)

### Megaloblastic Anemia

**B12 deficiency**:
- **CBC**: Macrocytic anemia (MCV >100 fL, often >110 fL)
- **Serum B12**: <200 pg/mL (deficient), 200-300 pg/mL (borderline)
- **Methylmalonic acid (MMA)**: Elevated (sensitive)
- **Homocysteine**: Elevated (less specific, also elevated in folate deficiency)
- **Peripheral smear**:
  - Macro-ovalocytes
  - Hypersegmented neutrophils (>5 lobes)
- **LDH**: Elevated (ineffective erythropoiesis)
- **Indirect bilirubin**: Elevated (intramedullary hemolysis)
- **Pancytopenia**: May be present
- **Anti-intrinsic factor antibodies**: Specific for pernicious anemia (sensitivity 50%)
- **Anti-parietal cell antibodies**: Sensitive but less specific

**Folate deficiency**:
- **CBC**: Macrocytic anemia
- **Serum folate**: <2 ng/mL
- **RBC folate**: <100 ng/mL (more reliable, reflects tissue stores)
- **MMA**: Normal (distinguishes from B12 deficiency)
- **Homocysteine**: Elevated
- **Peripheral smear**: Similar to B12 deficiency

### Hemolytic Anemia

**General hemolysis markers**:
- **Reticulocytosis**: >2%
- **Elevated indirect bilirubin**: Unconjugated hyperbilirubinemia
- **Elevated LDH**: Released from lysed RBCs
- **Decreased haptoglobin**: <25 mg/dL (binds free hemoglobin)
- **Elevated AST**: Mild elevation
- **Hemoglobinuria**: Intravascular hemolysis (dark urine)
- **Hemosiderinuria**: Chronic intravascular hemolysis

**Hereditary spherocytosis**:
- Spherocytes on smear
- Elevated MCHC
- Osmotic fragility test: Increased (historical)
- Eosin-5-maleimide (EMA) binding test: Flow cytometry
- Negative direct antiglobulin test (DAT)

**G6PD deficiency**:
- Rapid qualitative assay during acute episode may be falsely negative (older RBCs destroyed)
- Quantitative assay: 2-3 months after acute episode
- Bite cells, Heinz bodies on smear (requires special stain)

**Sickle cell disease**:
- Hemoglobin electrophoresis: HbS
- Peripheral smear: Sickle cells, target cells, Howell-Jolly bodies (functional asplenia)
- Newborn screening: Mandated in US

**Autoimmune hemolytic anemia**:
- **Direct antiglobulin test (DAT/Coombs)**: Positive
  - IgG: Warm AIHA
  - Complement (C3): Cold agglutinin disease
- **Peripheral smear**:
  - Warm AIHA: Spherocytes, polychromasia
  - Cold agglutinin: Agglutination, spherocytes
- **Cold agglutinin titer**: Elevated in cold agglutinin disease

**Microangiopathic hemolytic anemia**:
- **Schistocytes**: >1% on smear
- **Thrombocytopenia**: TTP, HUS, DIC
- **PT/aPTT**: Prolonged in DIC, normal in TTP/HUS
- **ADAMTS13 activity**: <10% in TTP

### Anemia of Chronic Disease

- Normocytic or microcytic anemia
- **Low serum iron**: <50 μg/dL
- **Low TIBC**: <250 μg/dL (distinguishes from iron deficiency)
- **Normal or elevated ferritin**: >100 ng/mL
- **Low transferrin saturation**: <20%
- **Elevated inflammatory markers**: ESR, CRP

### Sideroblastic Anemia

- Microcytic or dimorphic anemia
- **Elevated serum iron and ferritin**
- **Elevated transferrin saturation**: >50%
- **Bone marrow**: Ringed sideroblasts (>15% of erythroblasts) on Prussian blue stain

### Aplastic Anemia

- **Pancytopenia**: Anemia, leukopenia, thrombocytopenia
- **Low reticulocyte count**: <1%
- **Bone marrow biopsy**: Hypocellular (<25% cellularity), fatty replacement
- **No dysplasia or increased blasts**: Excludes myelodysplastic syndrome
- **Flow cytometry**: Evaluate for PNH (CD55, CD59)
- **Chromosomal breakage test**: Fanconi anemia (in children, young adults)

## Treatment

### Iron Deficiency Anemia

**Oral iron supplementation**:
- **Ferrous sulfate**: 325 mg (65 mg elemental iron) TID on empty stomach
  - Take with vitamin C (ascorbic acid) to enhance absorption
  - Avoid with calcium, tea, coffee, antacids
- **Alternative preparations**: Ferrous gluconate, ferrous fumarate
- **Duration**: Continue for 3-6 months after normalization to replete stores
- **Expected response**: Reticulocytosis in 5-7 days, increase in Hgb 1-2 g/dL per month
- **Side effects**: Nausea, constipation, dark stools, abdominal discomfort

**Intravenous iron**:
- **Indications**:
  - Intolerance to oral iron
  - Malabsorption (celiac disease, IBD, gastric bypass)
  - Ongoing blood loss exceeding oral replacement
  - Chronic kidney disease (especially on erythropoiesis-stimulating agents)
- **Preparations**: Iron sucrose, ferric gluconate, iron dextran, ferumoxytol, ferric carboxymaltose
- **Advantages**: Rapid repletion, better tolerability
- **Risks**: Anaphylaxis (rare with newer preparations), infusion reactions

**Treat underlying cause**:
- Address GI blood loss
- Manage menorrhagia
- Optimize nutrition

### Megaloblastic Anemia

**B12 deficiency**:
- **Cyanocobalamin or hydroxocobalamin**:
  - IM: 1000 μg daily for 1 week, then weekly for 1 month, then monthly maintenance
  - Oral: 1000-2000 μg daily (effective even in pernicious anemia due to passive absorption)
  - Intranasal, sublingual preparations available
- **Response**: Reticulocytosis in 3-5 days (peak 5-8 days), neurologic improvement (weeks to months)
- **Monitor potassium**: Risk of hypokalemia with rapid cell production

**Folate deficiency**:
- **Folic acid**: 1-5 mg PO daily
- **Replete B12 first**: Folate supplementation can mask B12 deficiency and worsen neurologic symptoms
- **Prophylaxis**: Pregnancy (400 μg daily), methotrexate therapy (1-5 mg daily)

**Treat underlying cause**:
- Dietary counseling
- Address malabsorption
- Adjust medications if possible

### Hemolytic Anemia

**Hereditary spherocytosis**:
- **Folic acid supplementation**: 1 mg daily (increased RBC turnover)
- **Splenectomy**: Indicated for severe anemia, gallstones, growth retardation
  - Vaccinate before splenectomy (pneumococcal, meningococcal, H. influenzae)
  - Post-splenectomy prophylaxis: Penicillin VK 250 mg BID (especially children <5 years)

**G6PD deficiency**:
- **Avoid triggers**: Oxidative stress-inducing medications, fava beans
- **Supportive care**: Hydration, transfusion if severe
- **Folic acid supplementation**: 1 mg daily

**Sickle cell disease**:
- **Hydroxyurea**: Increases HbF, reduces vaso-occlusive crises, acute chest syndrome, mortality
  - Dose: 15-35 mg/kg/day
  - Monitor CBC (myelosuppression)
- **L-glutamine**: Reduces oxidative stress, decreases crises
- **Crizanlizumab**: P-selectin inhibitor, reduces vaso-occlusive crises
- **Voxelotor**: Hemoglobin polymerization inhibitor, increases hemoglobin
- **Chronic transfusion therapy**: Stroke prevention, recurrent acute chest syndrome
- **Hematopoietic stem cell transplantation**: Curative, limited availability
- **Folic acid supplementation**: 1 mg daily
- **Vaccinations**: Pneumococcal, meningococcal, H. influenzae
- **Penicillin prophylaxis**: Children <5 years (functional asplenia)
- **Acute crisis management**: Hydration, analgesia, oxygen if hypoxic

**Warm autoimmune hemolytic anemia**:
- **Corticosteroids**: Prednisone 1 mg/kg/day, taper over weeks to months
- **Refractory cases**:
  - Splenectomy
  - Rituximab (anti-CD20)
  - Immunosuppressants: Azathioprine, cyclophosphamide
- **Avoid cold**: Can precipitate hemolysis
- **Transfusion**: If life-threatening (difficult to crossmatch)
- **Treat underlying cause**: CLL, lymphoma, SLE

**Cold agglutinin disease**:
- **Avoid cold exposure**
- **Rituximab**: First-line therapy
- **Corticosteroids**: Less effective than warm AIHA
- **Complement inhibitors**: Sutimlimab
- **Treat underlying lymphoproliferative disorder**

### Anemia of Chronic Disease

- **Treat underlying condition**: Inflammation, infection, malignancy
- **Erythropoiesis-stimulating agents (ESAs)**: If chronic kidney disease
  - Epoetin alfa, darbepoetin alfa
  - Target Hgb 10-11 g/dL (avoid >12 g/dL due to cardiovascular risks)
- **Iron supplementation**: If iron deficiency coexists
- **Transfusion**: If symptomatic, not responsive to treatment

### Sideroblastic Anemia

**Hereditary**:
- **Pyridoxine (vitamin B6)**: 50-200 mg daily
  - Some patients responsive (ALAS2 mutations)

**Acquired**:
- **Remove offending agent**: Alcohol, medications
- **Treat underlying MDS**: See hematologic malignancy treatment
- **Supportive care**: Transfusions, iron chelation (if transfusion-dependent)

### Aplastic Anemia

**Supportive care**:
- **Transfusions**: PRBCs (Hgb <7 g/dL), platelets (<10,000/μL or bleeding)
- **Avoid alloimmunization**: Leukoreduced, irradiated blood products
- **Infection prophylaxis**: G-CSF if neutropenic fever, antibiotics as needed

**Immunosuppressive therapy** (non-severe, not transplant candidate):
- **Horse anti-thymocyte globulin (ATG)**: 40 mg/kg/day for 4 days
- **Cyclosporine**: 5-10 mg/kg/day for 6-12 months, then taper
- **Corticosteroids**: Methylprednisolone during ATG to prevent serum sickness
- **Response rate**: 60-70%

**Hematopoietic stem cell transplantation** (HSCT):
- **First-line** for severe aplastic anemia, age <40, matched sibling donor
- **Success rate**: 80-90% long-term survival
- **Complications**: Graft-versus-host disease, graft failure

**Eltrombopag**:
- Thrombopoietin receptor agonist
- Refractory aplastic anemia
- Stimulates multilineage hematopoiesis

### Transfusion Therapy

**Packed red blood cells (PRBCs)**:
- **Indications**:
  - Symptomatic anemia
  - Hemoglobin <7 g/dL (restrictive strategy)
  - Hemoglobin <8 g/dL if cardiovascular disease
  - Acute blood loss with hemodynamic instability
- **Dose**: 1 unit raises Hgb ~1 g/dL
- **Type and crossmatch**: ABO and Rh compatible
- **Special considerations**:
  - Leukoreduced: Prevent febrile reactions, CMV transmission
  - Irradiated: Prevent transfusion-associated GVHD (immunocompromised)
  - Washed: Severe allergic reactions

## Complications

### Iron Deficiency Anemia

- **Impaired cognitive function**: Especially children
- **Decreased work capacity**: Fatigue, reduced productivity
- **Pregnancy complications**: Preterm delivery, low birth weight
- **Restless legs syndrome**
- **Pica**: Risk of toxin ingestion (lead from paint chips)

### Megaloblastic Anemia

**B12 deficiency**:
- **Irreversible neurologic damage**: If prolonged, severe
- **Subacute combined degeneration**: Spinal cord demyelination
- **Cognitive impairment, dementia**
- **Increased homocysteine**: Thrombotic risk (controversial)

**Folate deficiency**:
- **Neural tube defects**: If during pregnancy
- **Increased homocysteine**

### Hemolytic Anemia

- **Gallstones**: Pigment stones from chronic hemolysis
- **Hemolytic crisis**: Severe anemia requiring transfusion
- **Aplastic crisis**: Parvovirus B19 infection (temporary marrow suppression)
- **Iron overload**: From chronic transfusions (hemosiderosis)
- **Pulmonary hypertension**: Chronic hemolysis

**Sickle cell disease-specific**:
- **Stroke**: 10% of children
- **Acute chest syndrome**: Leading cause of death
- **Priapism**
- **Avascular necrosis**: Hip, shoulder
- **Chronic kidney disease**
- **Retinopathy**
- **Leg ulcers**

### Aplastic Anemia

- **Infections**: Bacterial, fungal (neutropenia)
- **Bleeding**: Intracranial hemorrhage, GI bleeding (thrombocytopenia)
- **Transfusion-related complications**: Alloimmunization, iron overload, infections
- **Clonal evolution**: MDS, acute leukemia (10-15%)
- **Paroxysmal nocturnal hemoglobinuria (PNH)**: 10-25% develop PNH clone

## Prognosis

### Iron Deficiency Anemia

- **Excellent prognosis** with treatment
- **Resolution**: Usually within 2-3 months of iron supplementation
- **Recurrence**: Common if underlying cause not addressed
- **Mortality**: Related to underlying cause (GI malignancy)

### Megaloblastic Anemia

**B12 deficiency**:
- **Excellent hematologic response**: Within weeks
- **Neurologic recovery**: Variable, may be incomplete if long-standing
- **Lifelong treatment**: Required for pernicious anemia, malabsorption

**Folate deficiency**:
- **Excellent prognosis**: Rapid response to supplementation
- **Prevention**: Essential in pregnancy

### Hemolytic Anemia

**Hereditary spherocytosis**:
- **Good prognosis**: Especially post-splenectomy
- **Complications**: Gallstones, rare hemolytic crises

**G6PD deficiency**:
- **Excellent prognosis**: If triggers avoided
- **Acute episodes**: Self-limited

**Sickle cell disease**:
- **Median survival**: 40-50 years (improving with hydroxyurea, newer therapies)
- **Mortality**: Acute chest syndrome, stroke, infections, multiorgan failure
- **Quality of life**: Impacted by chronic pain, frequent hospitalizations

**Autoimmune hemolytic anemia**:
- **Variable**:
  - Warm AIHA: 70-80% respond to steroids, 20-30% require second-line therapy
  - Cold agglutinin: Less responsive to steroids
- **Mortality**: Related to underlying disease (lymphoma, SLE)

### Aplastic Anemia

**Without treatment**:
- **Poor prognosis**: Median survival <6 months (severe)

**With treatment**:
- **HSCT**: 80-90% long-term survival (young patients, matched donors)
- **Immunosuppressive therapy**: 60-70% response rate, but relapses occur
- **Clonal evolution**: 10-15% develop MDS or AML over time

## Key Points

- Anemia is classified by MCV into microcytic (iron deficiency, thalassemia), normocytic (acute blood loss, hemolysis, chronic disease), and macrocytic (B12/folate deficiency, alcohol, MDS)
- Iron deficiency is the most common cause of anemia worldwide; workup includes serum iron, TIBC, ferritin, and search for source of blood loss
- Megaloblastic anemia from B12 deficiency causes neurologic symptoms (subacute combined degeneration); folate deficiency does not
- Hemolytic anemia features reticulocytosis, elevated indirect bilirubin and LDH, decreased haptoglobin; peripheral smear guides diagnosis
- Warm autoimmune hemolytic anemia (IgG) responds to corticosteroids; cold agglutinin disease (IgM) responds to rituximab
- Sickle cell disease management includes hydroxyurea, vaccinations, penicillin prophylaxis, and prompt treatment of crises
- Aplastic anemia presents with pancytopenia and hypocellular bone marrow; treatment is HSCT (young patients) or immunosuppression
- Anemia of chronic disease features low iron, low TIBC, and normal/elevated ferritin; treat underlying condition

## References

1. Camaschella C. Iron-Deficiency Anemia. N Engl J Med. 2015;372(19):1832-1843.

2. Stabler SP. Vitamin B12 Deficiency. N Engl J Med. 2013;368(2):149-160.

3. Steensma DP. Clinical Consequences of Clonal Hematopoiesis of Indeterminate Potential. Blood Adv. 2018;2(22):3404-3410.

4. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle Cell Disease. Lancet. 2017;390(10091):311-323.

5. Brodsky RA. Warm Autoimmune Hemolytic Anemia. N Engl J Med. 2019;381(7):647-654.

6. Young NS, Calado RT, Scheinberg P. Current Concepts in the Pathophysiology and Treatment of Aplastic Anemia. Blood. 2006;108(8):2509-2519.

7. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the Diagnosis and Management of Adult Aplastic Anaemia. Br J Haematol. 2016;172(2):187-207.

8. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron Deficiency Anaemia. Lancet. 2016;387(10021):907-916.

9. Longo DL, Prchal JT. Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis. N Engl J Med. 2015;373(10):975-976.

10. Janz TG, Johnson RL, Rubenstein SD. Anemia in the Emergency Department: Evaluation and Treatment. Emerg Med Pract. 2013;15(11):1-15.
